Evogliptin

Evogliptin (trade name Suganon, previously identified as DA-1229, Dong-A ST) is an antidiabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.[1] It was developed by the South Korean pharmaceutical company Dong-A.

References

  1. ↑ McCormack PL. (2015). "Evogliptin: First Global Approval.". Drugs. 75 (17): 2045–2049. doi:10.1007/s40265-015-0496-5. PMID 26541763.


This article is issued from Wikipedia - version of the 8/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.